Sign in
Active, not recruitingNo phase

Cephea South America Feasibility Study

Key facts

Who runs it
Abbott Medical Devices
Where
Brazil and Chile3 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
20 people, planned
Started
17 Jun 2025
Expected to end
Sept 2028
Type of study
Interventional
Treatments tested
  • Cephea Mitral Valve System
Record updated
11 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Mitral valve disease resulting in mitral regurgitation (MR ≥ Grade III) and/or severe mitral valve stenosis (mitral valve area ≤ 1.5cm²) per American Society of Echocardiography criteria
  • LVEF ≥ 30%
  • In the judgement of the Site Heart Team, transcatheter therapy is deemed more appropriate than open heart surgery

Who cannot take part

  • Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function
  • Need for emergent or urgent surgery

Where is this trial?

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.

The group in the trial

  • Cephea TMVRTreatment being tested

    Treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) with the Cephea Mitral Valve System

    Treatment: Cephea Mitral Valve System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
11 September 2026